This trial was completed in 2018, and Kaplan–Meier analysis of DFS for patients treated with GP2 immunotherapy showed 100% survival (0% breast cancer recurrence, p=0.0338) in the HER2/neu-positive adjuvant setting after a median of 5 years of follow-up. The gene discussed is ERBB2; the disease is breast carcinoma.